Skip to content

Study · Animal study (in vivo) · sheep · 2023

3 results

Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.

White A, Stremming J, Brown LD, Rozance PJ

Journal of developmental origins of health and disease28 Apr 2023Cited by 1 (Europe PMC)

PMID37114757 (opens in a new tab)PMCIDPMC10205682 (opens in a new tab)DOI10.1017/s2040174423000090 (opens in a new tab)PepBankPUB-37114757
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In late gestation fetal sheep, a 90-min IGF‑1 LR3 infusion decreased fetal plasma insulin concentrations.

    In plain wordsIn fetal sheep, a short IGF‑1 LR3 infusion lowered insulin levels in the blood.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseFetal plasma insulin concentration
    Study

    sheepn = 10

    Late gestation fetal sheep
    Comparator
    Vehicle control
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · infusion · 90 minutesAs given in this study (sheep).

    Source sentences

    Summary
    Fetal plasma insulin concentrations decreased with IGF-1 LR3 infusion (P < 0.05)
    1 context sentence
    Summary · context
    We first infused late gestation fetal sheep (n = 10) with either IGF-1 LR3 (IGF-1) or vehicle control (CON) and measured basal insulin secretion and in vivo GSIS utilizing a hyperglycemic clamp.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In late gestation fetal sheep, insulin concentrations during the hyperglycemic clamp were 66% lower with IGF‑1 LR3 infusion than with vehicle control.

    In plain wordsIn fetal sheep, insulin levels during a high-glucose test were lower with IGF‑1 LR3 than with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseInsulin concentration during hyperglycemic clamp
    Study

    sheepn = 10

    Late gestation fetal sheep
    Comparator
    Vehicle control
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · infusion · 90 minutesAs given in this study (sheep).

    Measurements

    Insulin reduction during hyperglycemic clamp
    66%
    IGF-1 LR3 vs CON

    Source sentences

    Summary
    and insulin concentrations during the hyperglycemic clamp were 66% lower with IGF-1 LR3 infusion compared to CON (P < 0.0001).
    1 context sentence
    Summary · context
    We first infused late gestation fetal sheep (n = 10) with either IGF-1 LR3 (IGF-1) or vehicle control (CON) and measured basal insulin secretion and in vivo GSIS utilizing a hyperglycemic clamp.
  3. 03LabEx vivo tissueEfficacy outcome

    In isolated fetal sheep islets, insulin secretion did not differ between islets from IGF‑1 LR3 and vehicle control infusions.

    In plain wordsIn islets taken from fetal sheep, insulin release did not differ between IGF‑1 LR3 and vehicle infusions.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeInsulin secretion in isolated fetal islets
    Study

    sheepn = 12

    Isolated fetal islets after 90-min in vivo infusion
    Comparator
    Vehicle control
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · infusion · 90 minutesAs given in this study (sheep).

    Source sentences

    Summary
    Insulin secretion in isolated fetal islets was not different based on infusion at the time of islet collection.
    1 context sentence
    Summary · context
    We then isolated fetal islets immediately following a 90-min IGF-1 or CON in vivo infusion and exposed them to glucose or potassium chloride to measure in vitro insulin secretion (IGF-1, n = 6; CON, n = 6).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.